SCHEMBL18383372

SCHEMBL18383372

N#Cc1nc2ccc(OCCCNC(=O)Cc3ccc4c(c3)C(=O)OC43c4ccc(O)cc4Oc4cc(O)ccc43)cc2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 1/20 0.44
▸ KCNH2 Q12809 2/20 0.42
▸ FTO Q9C0B1 9/20 0.41
▸ GSTP1 P09211 1/20 0.41
▸ ALB P02768 1/20 0.40
▸ NQO1 P15559 1/20 0.40
▸ ITPR3 Q14573 1/20 0.39
▸ FAP Q12884 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ SMAD3 P84022 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PRMT1 Q99873 1/20 0.38
▸ ACE2 Q9BYF1 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18806530 0.95 MIF (0.41) MIFKCNH2FTOGSTP1ALB
SCHEMBL13663814 0.85 NT5E (0.41) MIFKCNH2FTOALBNQO1
SCHEMBL13662233 0.78 NT5E (0.41) MIFKCNH2FTOALBNQO1
SCHEMBL13662226 0.77 KCNH2 (0.43) MIFKCNH2GSTP1ITPR3MEN1
SCHEMBL23169348 0.75 FTO (0.48) MIFKCNH2FTOGSTP1ALB
SCHEMBL18116829 0.74 KCNH2 (0.44) MIFKCNH2GSTP1NQO1MEN1
SCHEMBL25613623 0.74 ALB (0.54) MIFKCNH2FTOGSTP1ALB
SCHEMBL13637242 0.72 ITPR3 (0.33) KCNH2ITPR3FAP
SCHEMBL19835754 0.72 L3MBTL1 (0.48) KCNH2FTOGSTP1ALBITPR3
SCHEMBL19719052 0.70 FTO (0.52) KCNH2FTOGSTP1ALBITPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932365-B2 Protein labeling with cyanobenzothiazole conjugates PROMEGA CORPORATION (US) 2018-04-03 — — US disclosed
US-20170283456-A1 PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2017-10-05 — — US disclosed
US-9689868-B2 Protein labeling with cyanobenzothiazole conjugates PROMEGA CORPORATION (US) 2017-06-27 — — US disclosed
US-20170016888-A1 PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2017-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170283456-A1 PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES QPCTL, BCAT1, QPCT MIF 3045/4885KCNH2 3175/4885FTO 2936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback